title: A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data.
abstract: This study compared the cost and effectiveness of highly purified, human-derived follicle-stimulating hormone (FSH) (Bravelle) to recombinant FSH (Follistim) using Markov modeling and Monte Carlo simulation. One IVF treatment cycle resulted in costs of 11,584 dollars +/- 211 dollars for human-derived FSH and 12,762 dollars +/- 170 dollars for recombinant FSH, while three treatment cycles, holding the transition probabilities of the first cycle constant for the next two cycles, resulted in costs of 22,712 dollars +/- 1,107 dollars for human-derived FSH and 24,935 dollars +/- 1,205 dollars for recombinant FSH.
authors.affiliation: Hind T. Hatoum and Company, Chicago, Illinois, USA.
authors.forename: Hind T
authors.initials: HT
authors.lastname: Hatoum
authors.forename: William R
authors.initials: WR
authors.lastname: Keye
authors.forename: Richard P
authors.initials: RP
authors.lastname: Marrs
authors.forename: Surrey M
authors.initials: SM
authors.lastname: Walton
authors.forename: Dennis C
authors.initials: DC
authors.lastname: Marshall
mesh_terms: D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D005260:Female; D005307:Fertilization in Vitro / Q000191:economics*; D005640:Follicle Stimulating Hormone / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D008390:Markov Chains; D017059:Models, Econometric; D009010:Monte Carlo Method; D011247:Pregnancy; D011994:Recombinant Proteins / Q000191:economics* / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone